FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078075009> ?p ?o ?g. }

• W2078075009 endingPage "944" @default.
• W2078075009 startingPage "938" @default.
• W2078075009 abstract "To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target rash (TR)); to characterise the pharmacokinetics (PK) and pharmacodynamics (PD) of higher doses of erlotinib. Patients initially received erlotinib 150 mg per day. The dose was successively increased in each patient to that associated with a TR. Anticancer activity was evaluated. Plasma, skin, and hair were sampled for PK and PD studies. Erlotinib dose escalation to 200–475 mg per day was feasible in 38 (90%) of 42 patients. Twenty-four (57%) patients developed a TR, but 19 (79%) did so at 150 mg per day. Five (12%) patients, all of whom developed a TR, had a partial response. Median progression-free survival (PFS) was 2.3 months (95% CI: 1.61, 4.14); median PFS was 3.5 months and 1.9 months, respectively, for patients who did and did not experience a TR (hazard ratio, 0.51; P=0.051). Neither rash severity nor response correlated with erlotinib exposure. Intrapatient dose escalation of erlotinib does not appreciably increase the propensity to experience a maximal level of tolerable skin toxicity, or appear to increase the anticancer activity of erlotinib in NSCLC." @default.
• W2078075009 created "2016-06-24" @default.
• W2078075009 creator A5000921919 @default.
• W2078075009 creator A5000961519 @default.
• W2078075009 creator A5011819733 @default.
• W2078075009 creator A5011905014 @default.
• W2078075009 creator A5013449798 @default.
• W2078075009 creator A5015878526 @default.
• W2078075009 creator A5028833538 @default.
• W2078075009 creator A5048667036 @default.
• W2078075009 creator A5052225076 @default.
• W2078075009 creator A5057291927 @default.
• W2078075009 creator A5059398132 @default.
• W2078075009 creator A5059854677 @default.
• W2078075009 creator A5059997105 @default.
• W2078075009 creator A5060992997 @default.
• W2078075009 creator A5072572113 @default.
• W2078075009 creator A5082061757 @default.
• W2078075009 date "2011-08-30" @default.
• W2078075009 modified "2023-10-14" @default.
• W2078075009 title "Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer" @default.
• W2078075009 cites W1963568295 @default.
• W2078075009 cites W1964747353 @default.
• W2078075009 cites W1986001758 @default.
• W2078075009 cites W1990026184 @default.
• W2078075009 cites W2003278673 @default.
• W2078075009 cites W2029409133 @default.
• W2078075009 cites W2034642746 @default.
• W2078075009 cites W2041035291 @default.
• W2078075009 cites W2041620914 @default.
• W2078075009 cites W2043696829 @default.
• W2078075009 cites W2049484790 @default.
• W2078075009 cites W2097584581 @default.
• W2078075009 cites W2103134643 @default.
• W2078075009 cites W2105834225 @default.
• W2078075009 cites W2120181506 @default.
• W2078075009 cites W2126372889 @default.
• W2078075009 cites W2135836172 @default.
• W2078075009 cites W2138297714 @default.
• W2078075009 cites W2139248078 @default.
• W2078075009 cites W2158134441 @default.
• W2078075009 cites W2159023488 @default.
• W2078075009 cites W2162668815 @default.
• W2078075009 cites W2162724777 @default.
• W2078075009 cites W2168377135 @default.
• W2078075009 cites W2243704811 @default.
• W2078075009 cites W2409420104 @default.
• W2078075009 cites W4385789423 @default.
• W2078075009 doi "https://doi.org/10.1038/bjc.2011.332" @default.
• W2078075009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3185947" @default.
• W2078075009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21878940" @default.
• W2078075009 hasPublicationYear "2011" @default.
• W2078075009 type Work @default.
• W2078075009 sameAs 2078075009 @default.
• W2078075009 citedByCount "37" @default.
• W2078075009 countsByYear W20780750092012 @default.
• W2078075009 countsByYear W20780750092013 @default.
• W2078075009 countsByYear W20780750092014 @default.
• W2078075009 countsByYear W20780750092015 @default.
• W2078075009 countsByYear W20780750092016 @default.
• W2078075009 countsByYear W20780750092017 @default.
• W2078075009 countsByYear W20780750092018 @default.
• W2078075009 countsByYear W20780750092019 @default.
• W2078075009 countsByYear W20780750092020 @default.
• W2078075009 countsByYear W20780750092021 @default.
• W2078075009 countsByYear W20780750092022 @default.
• W2078075009 crossrefType "journal-article" @default.
• W2078075009 hasAuthorship W2078075009A5000921919 @default.
• W2078075009 hasAuthorship W2078075009A5000961519 @default.
• W2078075009 hasAuthorship W2078075009A5011819733 @default.
• W2078075009 hasAuthorship W2078075009A5011905014 @default.
• W2078075009 hasAuthorship W2078075009A5013449798 @default.
• W2078075009 hasAuthorship W2078075009A5015878526 @default.
• W2078075009 hasAuthorship W2078075009A5028833538 @default.
• W2078075009 hasAuthorship W2078075009A5048667036 @default.
• W2078075009 hasAuthorship W2078075009A5052225076 @default.
• W2078075009 hasAuthorship W2078075009A5057291927 @default.
• W2078075009 hasAuthorship W2078075009A5059398132 @default.
• W2078075009 hasAuthorship W2078075009A5059854677 @default.
• W2078075009 hasAuthorship W2078075009A5059997105 @default.
• W2078075009 hasAuthorship W2078075009A5060992997 @default.
• W2078075009 hasAuthorship W2078075009A5072572113 @default.
• W2078075009 hasAuthorship W2078075009A5082061757 @default.
• W2078075009 hasBestOaLocation W20780750092 @default.
• W2078075009 hasConcept C111113717 @default.
• W2078075009 hasConcept C112705442 @default.
• W2078075009 hasConcept C121608353 @default.
• W2078075009 hasConcept C126322002 @default.
• W2078075009 hasConcept C143998085 @default.
• W2078075009 hasConcept C197934379 @default.
• W2078075009 hasConcept C2776256026 @default.
• W2078075009 hasConcept C2777288759 @default.
• W2078075009 hasConcept C2778087573 @default.
• W2078075009 hasConcept C2778570526 @default.
• W2078075009 hasConcept C2779438470 @default.
• W2078075009 hasConcept C2909325608 @default.
• W2078075009 hasConcept C29730261 @default.
• W2078075009 hasConcept C71924100 @default.

• next